With global revenues expected to reach $290 billion by 2030, oncology is one of the most important development areas in our industry, with the potential to help the over 16 million people (about the population of New York) in the US living with cancer today.
True therapeutic alignment in drug development allows industry leaders to leverage experience, insights and capabilities and offer thoughtful, integrated solutions. In pursuing new products to help cancer patients see better outcomes, there are inherent, unique challenges and considerations.
Meet with us at 2023 ASCO Annual Meeting to discuss how you can mitigate challenges in your oncology pipeline.
Nick Kenny, Chief Scientific Officer, Medical and Scientific Strategy, Syneos Health